AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03477903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-954
Description: TAK-954 infusion
Study NCT03477903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: Metoclopramide infusion
Study NCT03477903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: 0.9% sodium chloride for injection
Study NCT03477903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: 0.9% sodium chloride for injection
Study NCT03582748 — intervention group
Intervention type: PROCEDURE
Intervention: sleeve gastrectomy
Description: removal of most of stomach as a bariatric surgical procedure
Study NCT03582748 — intervention group
Intervention type: PROCEDURE
Intervention: No sleeve gastrectomy
Description: Non-receipt of sleeve gastrectomy procedure
Study NCT03597529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: melatonin
Study NCT02481362 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAKE
Description: For the CAKE condition, participants will play a computer task to earn points for cake that they can consume.
Study NCT02481362 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: APRICOTS
Description: For the APRICOTS condition, participants will play a computer task to earn points for apricots that they can consume.
Study NCT03263897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: insufflation
Description: mobile interface driven insufflation of the ear canal
Study NCT03263897 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: insufflation
Description: mobile interface driven insufflation of the ear canal
Study NCT03263897 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: placebo insufflation
Description: mobile interface driven placebo insufflation of the ear canal
Study NCT00952731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral placebo
Description: Oral placebo taken daily for 4-10 weeks.
Study NCT00952731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afimoxifene
Description: 2mg/breast applied daily in the form of a gel for 4-10 weeks.
Study NCT00952731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen citrate
Description: 20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules) for 4-10 weeks.
Study NCT00952731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo gel
Description: Placebo gel applied to breasts daily for 4-10 weeks.
Study NCT02055664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine 0.2%
Study NCT02055664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorure de sodium 0.9%
Study NCT00704847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Salmon Calcitonin
Description: 0.8mg SMC021, twice daily
Study NCT00704847 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Salmon Calcitonin (Placebo)
Description: 0.8mg Placebo, twice daily
Study NCT01811316 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Probiotics
Study NCT01811316 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Study NCT04223557 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: focused power ultrasound treatment
Description: Patients will be placed in the lateral decubitus position and receive treatment with sequential bilateral PRF ablation. Before the treatment, a professional sonographer will be responsible for the length, thickness, and width of PRF sac measurement and localisation, and utilise the ultrasonic diagnostic transducer to delineate the targeted region. The treatment will launch layer-by-layer. After confirming accurate localization of the treatment, layer-by-layer PRF ablation will be performed on the patients. The device generates and delivers a pattern of conic-shaped ultrasound energy to the PRF sac noninvasively. The treatment of FPU-mediated PRF ablation will be implemented once.
Study NCT04223557 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: Participants will receive the same procedure as those in the FPU treatment including PRF ultrasonic measurement and localization and focused ultrasound treatment parameters setting, except that no energy will be delivered to the PRF.
Study NCT00303459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosentan
Description: bosentan/62.5 mg tablet/b.i.d. for 4 weeks then bosentan/125 mg tablet/b.i.d.
Study NCT00303459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching bosentan placebo/b.i.d.
Study NCT01025791 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MK-8266 1.0 mg
Description: MK-8266 1.0 mg oral capsule. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.
Study NCT01440933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: 1ml/kg of the study solution containing 60 mg/ml of magnesium sulphate are given intravenously over 15 minutes in the conscious patient. After anaesthesia induction and calibration of neuromuscular monitoring (TOF Watch SX - acceleromyography) 0,6 mg/kg of rocuronium is given intravenously. After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) (PTC 2) or reappearance of 2 twitches of the Train of four (superficial neuromuscular block) 4 mg/kg (deep neuromuscular block) or 2 mg/kg (superficial neuromuscular block) of Sugammadex are given intravenously.
Study NCT01440933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: 1ml/kg of the study solution containing physiologic saline are given intravenously over 15 minutes in the conscious patient. After anaesthesia induction and calibration of neuromuscular monitoring (TOF Watch SX - acceleromyography) 0,6 mg/kg of rocuronium is given intravenously. After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) (PTC 2) or reappearance of 2 twitches of the Train of four (superficial neuromuscular block) 4 mg/kg (deep neuromuscular block) or 2 mg/kg (superficial neuromuscular block) of Sugammadex are given intravenously.
Study NCT02203500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacidipine
Study NCT02203500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Study NCT04347733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide 40mg/mL
Description: We aimed to examine the therapeutic efficacy of the combination of hyaluronidase and steroid injection for adhesive capsulitis and to determine whether such a combination therapy might enable the total amount of steroids to be reduced.
Study NCT04347733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide 40mg/mL
Description: We aimed to examine the therapeutic efficacy of the combination of hyaluronidase and steroid injection for adhesive capsulitis and to determine whether such a combination therapy might enable the total amount of steroids to be reduced.
Study NCT04347733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronidase Injection
Description: We aimed to examine the therapeutic efficacy of the combination of hyaluronidase and steroid injection for adhesive capsulitis and to determine whether such a combination therapy might enable the total amount of steroids to be reduced.
Study NCT03001440 — intervention group
Intervention type: OTHER
Intervention: KAB survey
Description: The KAB survey will be conducted among study population to evaluate their understanding of the potential serious risk with the use of ZYBAN. The 20 minutes survey can be completed either online or through a telephone interview.
Study NCT01292863 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Conventional peritoneal dialysis solution
Description: Daily dialysis solution to be used for 3 months in crossover fashion.
Study NCT01292863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Novel biocompatible dialysis solution
Description: Daily dialysis solution to be used for 3 months in crossover fashion.
Study NCT02432300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Builder
Description: Total of 8 therapy sessions with the Emotion Builder over approximately four (4) weeks (2 sessions a week)
Study NCT04553549 — intervention group
Intervention type: DEVICE
Intervention: Transradial approach
Description: Patients who are undergoing endovascular intervention will be enrolled into the study. As the metrics analyzed in this study are already normally collected, this study can be considered as a secondary use of the data. The procedure will be done using standard criteria as per operator preference. All interventional cases at the study institution undergo a radial first approach, meaning that the access site of choice is the radial artery. The investigators will measure the radial artery size to ensure that the artery is greater than 2.4 mm in order to use the Infinity catheter (8Fr).
Study NCT04495426 — intervention group
Intervention type: OTHER
Intervention: Non-interventional study
Description: There are no treatments to stop or even slow down the progression of this disease although there are treatments that temporarily improve the symptoms, such as anti-seizure medications.
Study NCT03481777 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Conditioning
Description: RIC is commonly achieved by inflation of a blood pressure cuff to induce 5-minute cycles of limb ischemia alternating with 5 minutes of reperfusion.
Study NCT03481777 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Remote Ischemic Conditioning
Description: Sham Comparator (Sham-RIC)
Study NCT04286451 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Restriction
Description: Women will be undergo 4 nights of sleep restriction.
Study NCT04286451 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habitual Sleep
Description: Women will be undergo 4 nights of habitual sleep.
Study NCT05945719 — intervention group
Intervention type: BEHAVIORAL
Intervention: Behavioral therapy
Description: Behavioral and supportive therapy
Study NCT03180216 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Virus Specific T cells (VSTs)
Description: This Phase I dose-escalation trial is designed to evaluate the safety of rapidly generated multivirus-specific T-cell products with antiviral activity against CMV, EBV, adenovirus, HHV6, BK virus, JC virus, and human parainfluenza-3 (HPIV3), derived from eligible HSCT donors.~In this trial, we will utilize a rapid generation protocol for broad spectrum multivirus-specific T cells for infusion to recipients of allogeneic hematopoietic stem cell transplant (HSCT), who are at risk of developing EBV, CMV, adenovirus, HHV6, BKV, JCV and/or HPIV3, or with PCR/culture confirmed active infection(s) of EBV, CMV, adenovirus, HHV6, BKV, JCV, and/or HPIV3 that has failed to resolve with at least 14 days of standard antiviral therapy (if available and tolerated). These cells will be derived from HSCT donors, and the study agent will be assessed at each dose for evidence of dose-limiting toxicities (DLT).
Study NCT01650649 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lofexidine-matching sugar pill
Description: Lofexidine-matching sugar pill tablets titrated in ascending doses of 1 tablet starting at 2 tablets QID (e.g. Day 1 2 tablets QID, Day 2 3 tablets QID, etc)as described in the treatment arm. Option to down-titrate to 1 tablet QID if 2 tablets not initially tolerated.
Study NCT04975412 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Whole blood zinc level
Description: whole blood zinc levels determined through ashing acid digestion-inductively coupled plasma (ICP) using Shimadzu ICPS-7510, an inductively coupled plasma emission spectrometer.
Study NCT05036837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZOPROMAF_SEQ1
Description: OZOPROMAF protocol consists of: local superficial anesthesia by EMLA® cream, intra-tissue injection of a 15 ml OxigenOzone (mixture by 26Gx 1⁄2 - 0.45x13mm needle into the mucosal margin surrounding the bone exposure or around the situs already evidenced by CT scan. It is applied on 7-15 days, depending on the patient compliance, until the formation of sequestrum and clinical healing (T1).~Pain intensity is assessed by means of a questionnaire for pain and/or other symptoms evaluation before and after the protocol, based on numerical rating scale (NRS).~After resolution (T1), follow-up visits are scheduled to confirm the healing of MRONJ at 1 (T2), 3, 6 (T3), 12 (T4), 18- 24 months (T5).~Radiographic evaluations of bone healing are scheduled at T3 and T4.~Positive outcomes for the OZOPROMAF protocol are evaluated at T1 as no clinical signs of acute phlogosis and no symptoms compatible with MRONJ; at T5 as clinical healing and no radiological signs of MRONJ.
Study NCT03980509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Curcumin is an extract from turmeric
Study NCT05178745 — intervention group
Intervention type: DRUG
Intervention: Fluorouracil
Description: Pharmaceutical Form: solution for injection Route of Administration: intravenous (IV), intravenous or intra-arterial infusion
Study NCT05178745 — intervention group
Intervention type: DRUG
Intervention: Aflibercept
Description: Pharmaceutical Form: concentrate solution for infusion Route of Administration: IV infusion
Study NCT05178745 — intervention group
Intervention type: DRUG
Intervention: Irinotecan
Description: Pharmaceutical Form: solution for injection Route of Administration: IV infusion
Study NCT02993315 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nDC vaccination
Study NCT02128113 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Ophthalmic Solution
Description: Opthalmic suspension manufactured to mimic RTA 408 suspension
Study NCT02128113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Ophthalmic Suspension 0.5%
Description: 0.5% ophthalmic suspension of RTA 408
Study NCT02128113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Ophthalmic Suspension 1%
Description: 1% ophthalmic suspension of RTA 408
Study NCT01645124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea
Study NCT01645124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Study NCT01645124 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phlebotomy
Study NCT01645124 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phlebotomy
Study NCT03784170 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: FemPulse System
Description: Device therapy with the FemPulse System
Study NCT03784170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FemPulse System
Description: Device therapy with the FemPulse System
Study NCT00355888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBP-426
Description: Dose escalation starting at 6 mg/m2, IV (in the vein) on Day 1 of each 21-day cycle. Number of Cycles: Up to 6 cycles, until unacceptable toxicity, disease progression, or intercurrent illness requires treatment discontinuation. Patients may continue treatment beyond 6 cycles if the Investigator determines that additional treatment would provide further benefit for the patient as long as toxicity remains acceptable.
Study NCT00936416 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inulin and PAH clearance and MRI
Description: GFR and renal blood flow estimation by Inulin and PAH clearance will be performed in the Renal Physiology Lab for approximately 2.5 hours;~The MRI test will be performed afterwards at Medical Imaging department and last about 45 minutes.
Study NCT03987243 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Structured Pressure Ulcer Prevention Education
Description: Structured education for performance weight shift maneuvers and pressure ulcer prevention will occur during the initial visit for each subject. The education method used aligns with principles of the social cognitive theory to facilitate learning. The purpose in providing the education is to ensure all of the participants receive uniform instruction in how to perform weight shifts and to facilitate understanding of the importance of completing them as a protective measure against pressure ulcer development. Because each participant will come into the study at varying levels of understanding about pressure ulcer risk and knowledge of how to complete weight shift maneuvers, the education component is critical to ensure all participants are provided with the same information in the same way.
Study NCT03987243 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mobile Seat Interface Pressure Mapping System (IPM)
Description: This mobile IPM system was designed to provide visual information about seat interface pressure distribution to compensate for lack of sensation on the sitting surface. This variable will be toggled on and off between the intervention and control phases of the study. The participants will have access to the visual feedback while learning how to complete weight shift maneuvers at the initial visit and then again at home during the intervention phases (weeks 2 and 4). During the control phases (weeks 1 and 3), they will not have access to the visual feedback from the pressure map
Study NCT00978016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arbaclofen placarbil-Cohort 1
Description: After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 20 mg QD) for 7 weeks including titration and taper periods
Study NCT00978016 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Cohort 5
Description: After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (placebo) for 7 weeks including titration and taper periods
Study NCT00978016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arbaclofen placarbil-Cohort 2
Description: After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 40 mg QD) with for 7 weeks including titration and taper periods
Study NCT00978016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arbaclofen placarbil-Cohort 3
Description: After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 20 mg BID) for 7 weeks including titration and taper periods
Study NCT00978016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arbaclofen placarbil-Cohort 4
Description: After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 30 mg BID) for 7 weeks including titration and taper periods
Study NCT00978016 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PPI
Description: Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD
Study NCT00978016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI
Description: Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD
Study NCT02132949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Participants will receive 5-fluorouracil 500 mg/m\^2 IV on Day 1 of each cycle q3w.
Study NCT00152828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Study NCT02132949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Participants will receive cyclophosphamide 600 milligrams per square meter (mg/m\^2) intravenous (IV) given on Day 1 of each cycle q2w.
Study NCT02132949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Participants will receive docetaxel at a starting dose of 75 mg/m\^2 IV for the first cycle and the dose may be escalated to 100 mg/m\^2 for subsequent cycles q3w.
Study NCT02132949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Participants will receive doxorubicin 60 mg/m\^2 IV on Day 1 of each cycle q2w.
Study NCT02132949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Participants will receive epirubicin 100 mg/m\^2 IV on Day 1 of each cycle q3w.
Study NCT02132949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Participants will receive paclitaxel 80 mg/m\^2 IV given weekly.
Study NCT02132949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Participants will receive pertuzumab at a loading dose of 840 milligrams (mg) IV loading dose, then 420 mg IV q3w.
Study NCT02132949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Participants will receive trastuzumab at a loading dose of 8 milligrams per kilogram (mg/kg) IV, then 6 mg/kg IV q3w.
Study NCT03352466 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NasoShield
Description: NasoShield is an adenovirus-vectored anthrax vaccine.
Study NCT01025791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match MK-8266 0.1 or 1.0 mg. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.
Study NCT02993315 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo injection